Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.50 |
| ▸ | CDK2 | P24941 | 7/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273547 | 0.90 | KCNH2 (0.48) | KCNH2CDK2HDAC1CDK1HDAC3 | |
| SCHEMBL272753 | 0.88 | KCNH2 (0.51) | KCNH2CDK2HDAC1CDK1HDAC3 | |
| SCHEMBL278786 | 0.87 | CDK2 (0.61) | KCNH2CDK2HDAC1CDK1HDAC3 | |
| SCHEMBL327893 | 0.82 | KCNH2 (0.46) | KCNH2CDK2HDAC1CDK1HDAC3 | |
| SCHEMBL274438 | 0.79 | KCNH2 (0.43) | KCNH2CDK2CDK1 | |
| SCHEMBL272439 | 0.79 | CDK2 (0.53) | KCNH2CDK2CDK1HDAC3HDAC2 | |
| SCHEMBL13522816 | 0.78 | CDK2 (0.60) | KCNH2CDK2CDK1 | |
| SCHEMBL273901 | 0.78 | KCNH2 (0.47) | KCNH2CDK2HDAC1CDK1HDAC3 | |
| SCHEMBL274273 | 0.76 | HDAC1 (0.54) | KCNH2HDAC1HDAC3HDAC2 | |
| SCHEMBL2638082 | 0.75 | KCNH2 (0.44) | KCNH2HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2010009139-A2 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | HDAC1, CDK9, CDK2 | KCNH2 3847/4885CDK2 3/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.